Dr. Rachit Kumar

"Dr. Rachit Kumar is a radiation oncologist specializing in genitourinary and gastrointestinal cancers. He is dedicated to patient-centered care, finding the most effective outcome for each patient and using the latest advances to minimize treatment time and side-effects. Dr. Kumar is frequently published in peer-reviewed journals on new methods of radiation therapy and the benefits to patient outcomes. He is a member of the Johns Hopkins Kimmel Cancer Center and treats patients at both Sibley Memorial Hospital and Suburban Hospital. Selected Publications Kumar R, Tchelebi LT, Anker CJ, Sharma N, Bianchi NA, Dragovic J, Goodman KA, Herman JM, Jiang Y, Jones WE, Kenney TJ, Lee P, Kundranda MK, Russo S, Small W, Suh WW, Yee N, and Jabbour SK. “American Radium Society (ARS) Appropriateness Use Criteria (AUC) for Loco-Regional Gastric Adenocarcinoma: Systemic Review and Guidelines.” American Journal of Clinical Oncology. 2022 Sep 1;45(9):391-402. Rooney MK, Traube B, Khan MK, Kumar R, and Walker GV. “Factors associated with image guided radiation therapy image rejection in a multi-site institution.” JCO Oncology Practice. Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S, Chapin BF, Nguyen QN, Davis JW, Frank SJ, Navai N, McGuire SE, Anscher M, Pisters L, Pettaway CA, Kumar R, Linson P, Tripuraneni P, Tomaszewski JJ, Patel AB, Augspurger M, and Kuban DA. “Contemporary Prostate Cancer Treatment Choices in Multidisciplinary Clinics Referenced to National Trends.” Cancer. Tang C, Lei X, Smith GL, Pan HY, Hoffman K, Kumar R, Chapin BF, Shih YC, Frank SJ, and Smith BD. ""Influence of Geography on Prostate Cancer Treatment Coice: An Analysis of the National Medicare Database."" International Journal of Radiation Oncology Biology Physics. Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Aparicio A, Zurita-Saavedra A, Chun S, Reddy J, Choi S, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Tu SM, Pilie P, Kovitz C, Kumar R, Roberts T, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn and PG. “Addition of local consolidative therapy to intermittent hormone therapy for oligometastatic prostate cancer (EXTEND): a multicenter randomized phase II basket trial.” JAMA Oncology.".

Dr. Kumar is rated as an Experienced provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatoblastoma, and Prostate Cancer.

His clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.